Alivio Therapeutics

Alivio Therapeutics Pioneers New Strategy of Targeted Disease Immunomodulation for the Treatment of a Range of Chronic and Acute Inflammatory Diseases. Targeted disease immunomodulation involves adjusting the immune system only at the site of disease within the body, with minimal impact on the broader immune system. This long-sought-after approach holds the potential to treat a variety of chronic and acute inflammatory diseases, including those that are otherwise difficult to address. Alivio Therapeutics has exclusive rights to an inflammation-targeting technology based on the research of Dr. Karp and Dr. Robert Langer. This is the first technology to consistently demonstrate the targeted delivery of immunomodulatory compounds to inflamed tissues, which could lead to significantly improved therapeutic outcomes and substantially reduced systemic effects. The platform has been validated across multiple laboratories and preclinical models of inflammation, including models where inflammation occurs in different parts of the body. This technology can be used with single or combination drugs and administered orally or through other routes. Through this platform, Alivio Therapeutics is committed to addressing dozens of conditions where inflammation is a core component of the underlying disease pathology but lacks targeted and effective treatment options.